MAM
Dettol Handwash in new packs
MUMBAI: Reckitt Benckiser has launched Dettol Liquid Handwash in new packs.
The range that claims to give effective protection against a wide range of unseen germs daily will now be available in an all new and easy to hold shape, new fragrances and new packaging.
Dettol Liquid Handwash has four variants including Dettol Skincare, Dettol Fresh, Dettol Sensitive and Dettol Original which comes with new formulations.
All the four variants are available in pump packs of 250ml and / or 135ml. The new handwash bottles come with a wider pump for easier use and a wider mouth for easier refill. The refill packs are also available in 185ml and 900ml.
Reckitt Benckiser India chairman MD Chander Mohan Sethi said, “Our new Dettol Liquid Handwash bottles with wider pumps are in line with Dettol‘s primary focus of providing germ protection. Dettol, our flagship brand is India‘s most trusted brands and is considered as the gold standard for protection against germs and infections.”
MAM
Cipla appoints Achin Gupta as MD and global CEO
Veteran pharma leader with 20-plus years takes charge from 1 April 2026, succeeding current MD.
MUMBAI: Cipla’s next chapter just got a seasoned prescription because when it comes to leading a pharma giant, Achin Gupta knows exactly which dose delivers results. The Mumbai-based drugmaker announced on 23 February 2026 that Achin Gupta, currently global chief operating officer, will step up as managing director and global chief executive officer from 1 April 2026. He succeeds the outgoing leadership team and will steer Cipla’s worldwide operations, market expansion, operational efficiency, and innovation pipeline across its broad portfolio of generics, specialty drugs, and consumer healthcare treatments.
Gupta brings more than 20 years of pharmaceutical industry experience to the corner office. Before rejoining Cipla, he spent over eight years at Glenmark Pharmaceuticals in senior roles, having also worked there earlier between 2004 and 2012. His career path also includes key stints at Abbott Laboratories and management consulting firm A.T. Kearney, giving him a well-rounded view of global pharma strategy, operations, and growth.
In his current COO role, Gupta has already been deeply involved in streamlining Cipla’s supply chain, boosting manufacturing agility, and driving digital transformation moves that positioned the company strongly amid post-pandemic supply challenges and rising competition. As MD and Global CEO, he’ll now have full accountability for executing Cipla’s long-term vision, from deepening presence in key markets like the US, Europe, and emerging regions to accelerating R&D in complex generics and biosimilars.
The appointment comes at a pivotal time for Cipla, as the industry navigates pricing pressures, regulatory shifts, and the push for affordable innovation in chronic therapies. Gupta’s track record of scaling operations and delivering consistent performance makes him a logical internal choice to keep the momentum going.
For a company that’s long been a household name in affordable medicines, this leadership handoff is less about a big shake-up and more about steady continuity with fresh energy ensuring the next dose of growth is as effective as the last.
